| Followers | 8 |
| Posts | 2087 |
| Boards Moderated | 0 |
| Alias Born | 07/31/2006 |
Monday, November 25, 2013 10:03:55 AM
Apparently something related to Saliva Diagnostics. Hates the CEO for reasons completely unrelated to NanoViricides, but takes his grudge out on us and this company because it's the only target he can find. Self proclaimed "flipper" and "player" of the stock, admits to selling short on price runs, and brags as to supposed profits from these activities:
"I was in the bridge loan and IPO of Saliva diagnostics, FYI"
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=52523092
"I shorted in the 1.30's on that trip"
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=54268342
"At least I'm consistent! No secret, I have little respect for the CEO and play the stock! "
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=52210247
"am only in the company because there are lots of folks buying and its been a great source of income [for me]."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=49285962
"personal grudge, I admit and the only way to compensate is play the swings"
"I've pocketed over $75.000k and now have 25K free shares after selling another 10K in the mid 1.30s. One thing a flipper can depend on with this stock, someone will PR something to have the price run."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=47494799
"I was in the bridge loan and IPO of Saliva diagnostics, FYI"
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=52523092
"I shorted in the 1.30's on that trip"
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=54268342
"At least I'm consistent! No secret, I have little respect for the CEO and play the stock! "
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=52210247
"am only in the company because there are lots of folks buying and its been a great source of income [for me]."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=49285962
"personal grudge, I admit and the only way to compensate is play the swings"
"I've pocketed over $75.000k and now have 25K free shares after selling another 10K in the mid 1.30s. One thing a flipper can depend on with this stock, someone will PR something to have the price run."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=47494799
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
